In Vivo Tumor Models

In vivo tumor xenograft models, including CDX, PDX, syngeneic hPBMC, HSC, immune checkpoint

WuXi Biology has significant experience in oncology drug discovery. We offer a large collection of tumors models for small & large molecule drug discovery.

  • Cell line-derived xenograft (CDX) tumor models
  • Patient-derived xenograft (PDX) tumor models
  • Syngeneic tumor models
  • Human immune checkpoint gene KI mouse models
  • hPBMC/HSC humanized models

Cell line-derived xenograft (CDX) tumor models

  • 280+ validated models covering full range of cancer types
  • 77+ cell lines derived from PDX models
  • Available data of sensitivities to SOC (standard of care)
  • Imaging-based orthotopic/metastatic tumor models
  • Brain/bone metastatic models of lung/breast cancer cell lines
CDX, cell line-derived xenograft tumor models, derived from PDX models, SOC data, multiple cancer types
*: validated with SOC compound

28 Luciferase Labelled Orthotopic/Metastatic Tumor Models

  • Cover 16 tumor types
  • Bioluminescent imaging system in SPF barrier
Orthotopic, metastatic tumor models, luciferase, multiple cancer types
O: orthotopic model  M: metastatic mode  S: validated with SOC

Patient-derived xenograft (PDX) tumor models


  • 1380+ PDX models covering full range of cancer types
  • Fully-characterized models with genetic, molecular and pharmacological profiling
  • Drug-resistant PDX models available
  • in vitro screening and derivative PDXC/PDXO models
  • IO-PDX panel with hPBMC humanization
PDX, patient-derived xenograft tumor models, including drug-resistant tumor models

A Comprehensive PDX Collection of Asia Prevalent Tumors

Comprehensive collection of prevalent tumors, including HCC, gastric, cervical, esophageal, ovarian cancers

Syngeneic tumor models

  • 80+ syngeneic models (mouse, rat, hamster)
  • Responsiveness to immune checkpoint inhibitors (PD-1, PD-L1, CTLA-4, etc.)
  • Tumor-infiltrating leukocytes (TILs) map
  • WES, RNA-seq and scRNA-seq characterization
Syngeneic tumor models, mouse, rat; responsive to immune checkpoint inhibitors, PD-1, PD-L1, CTLA-4
Note: 16 models with reference compound treatment data were marked as S, 17 models with genomic profiling data were marked with GP, 12 models with baseline TIL data were marked as T

hPBMC/HSC Humanized Models

hPBMC Humanized Models

  • Established models for immune-checkpoint inhibitor and bi-specific antibody candidates in a human-resembling immune system.
  • Annotation for both immune cells (phenotyping, biomarker, functions) and tumor cells (expression, mutation, etc.)
  • Different PBMC delivery systems (systemic injection or co-inoculation with tumor)

HSC Humanized Models

  • Available humanized models from CIEA combine with WuXi PDX/CDX models.
  • Customizable with human cytokine transgenic mice (GM-CSF/hIL-3 or hIL-2) to improve the reconstitution of myeloid lineage.

A List of Established hPBMC Humanized Models

hPBMC and HSC humanized tumor models, established for immune checkpoint inhibitors, bispecific antibodies
Bold: has been applied for efficacy study        *Popular models

Genetically engineered models

  • 48 engineered cell lines based on construct overexpression or gene knock-in
  • Pharmacologically validated in vitro and in vivo
  • Focusing at drug-resistant mutation introduction and IO-related checkpoint humanization
  • Example targets: EGFR, ROS1, ALK, RET, FLT3, BTK, Claudin18.2, PD-L1, etc.

Human immune checkpoint gene KI mouse models

KI (Knock-in) mice offer the possibility to study clinical grade checkpoint antibodies targeting human checkpoints in the context of a fully functional immune system

  • Collection of various targets and background mouse strains
  • Validated with launched or most advanced clinical grade checkpoint antibodies
  • Double checkpoint KI mice customizable for combination (PD1 + OX40, PD1 + TIM3 etc.)
Human immune checkpoint gene knock-in KI mouse models, PD-1, CTLA-4
Human immune checkpoint gene knock-in KI mouse models, PD-1, CTLA-4, CD137